Cancer Treatment Today

Athough CT remains the gold standard for the staging and follow-up of malignant lymphomas, 18F-FDG PET has a potential role in accurately staging disease and in predicting response to therapy.  On the other,  guidelines do not recommend MRI for surveillance. The most common lymphoma is Diffuse Large B0cell Lymphoma(DLBCL).  2012 NCCN Guidelines for DLBCL on p. BCEL-4 recommend CT no more often than every 6 months for 2 years after completion of

The American College of Physicians (ACP) and the American Pain Society (APS) have issued a comprehensive joint clinical practice guideline for the diagnosis and treatment of low back pain, which is published in the October 2, 2007 issue of the Annals of Internal Medicine. For patients with nonspecific low back pain, clinicians should not routinely order imaging studies, including radiographs, computerized tomography (CT) scans, magnetic resonance

Although CT remains the gold standard for the staging and follow-up of malignant lymphomas, 18F-FDG PET has a potential role in accurately staging disease and in predicting response to therapy. On the other hand, guidelines do not recommend PET routinely for surveillance. NCCN Guidelines for DLBCL on p. BCEL-4 recommend CT no more often than every 6 months for 2 years after completion of treatment, then only as clinically indicated. In contrast to

The guidelines recommend CT for routine followup of renal cel carcinoma patients on active treatment. Some guidelines recommend PET as well as an alternative or to supplement CT; however, CT remains the standard imaging modality for restaging. In regard to PET/CT, little reliable information exists. There is currently limited experience with FDG-PET and renal cell carcinoma. One of the first studies evaluating 29 patients with solid renal masses

The combination of magnetic resonance spectroscopy (MRS) and imaging (MRI) has led to mapping metabolites from normal and neoplastic tissue within the time limits of a routine study. MRSI (magnetic resonance spectroscopy imaging) detects metabolites that contain protons, phosphorus, fluorine, or other nuclei. This allows radiologists and oncologists to apply MRSI as an assessment of function (uptake) to supplement anatomic information in research

PROSTASCINT is the first monoclonal antibody-based agent that targets prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. The study that supports its use, “Capromab pendetide (ProstaScint) imaging with central abdominal uptake: poor outcomes for prostate cancer patients,” by Haseman, et al., was presented at the 2007 Annual Meeting of the American Urological Association taking place May 19-24, 2007 in

Histiocytosis is a rare disease that involves hystiocytes. The disease can range from limited involvement that spontaneously regresses to progressive multiorgan involvement that can be chronic and debilitating. In some cases, the disease can be life-threatening.It is approximated that histiocytosis affects 1 in 200,000 children born each year in the United States. The disease us rare and not much is known securely about how to treat it. Because of

Some sources: Pavlov H, Saboeiro GR, Campbell SE, Dalinka MK, Daffner RH, DeSmet AA, El-Khoury GY, Kneeland JB, Manaster BJ, Morrison WB, Rubin DA, Schneider R, Steinbach LS, Weissman BN, Haralson RH III, Expert Panel on Musculoskeletal Imaging. Acute trauma to the knee [online publication], Reston (VA): American College of Radiology (ACR); 2005. 9p. [97 references]   American College of Radiology Practice Guideline for the Performance and Interpretation

18F-Fluoride is a different kind of PET scan, which uses sodium fluoride instead of technetium. It is more PET avid than FDG PET. Society of Nuclear Medicine says this: " No appropriateness criteria have been developed to date for this procedure. PET/CT 18F bone scans may be used to identify skeletal metastases, including localization and determination of the extent of disease. Insufficient information exists to recommend the following indications

Lay Summary: PET has become an accepted tool for determining the extent of newly diagnosed cervical cancer and for following effects of treatment NCCN recently (8/07) revised its staging recomendations and lists PET as a recommended staging modlity. Positron-emission tomography (PET) scan is no longer optional for ≥ stage IB2 disease and is now recommended as part of the workup. Whole-body positron emission tomography (PET) completed after cervical